WO2002003915A3 - Methods of producing weight loss and treatment of obesity - Google Patents

Methods of producing weight loss and treatment of obesity Download PDF

Info

Publication number
WO2002003915A3
WO2002003915A3 PCT/US2001/021509 US0121509W WO0203915A3 WO 2002003915 A3 WO2002003915 A3 WO 2002003915A3 US 0121509 W US0121509 W US 0121509W WO 0203915 A3 WO0203915 A3 WO 0203915A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
obesity
treatment
weight loss
producing weight
Prior art date
Application number
PCT/US2001/021509
Other languages
French (fr)
Other versions
WO2002003915A2 (en
Inventor
Walter E Kozachuk
Original Assignee
Walter E Kozachuk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter E Kozachuk filed Critical Walter E Kozachuk
Priority to CA002415760A priority Critical patent/CA2415760A1/en
Priority to AU7325601A priority patent/AU7325601A/en
Priority to AU2001273256A priority patent/AU2001273256B2/en
Priority to EP01952515A priority patent/EP1305034A4/en
Publication of WO2002003915A2 publication Critical patent/WO2002003915A2/en
Publication of WO2002003915A3 publication Critical patent/WO2002003915A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Abstract

Methods are disclosed for the acute and chronic treatment of obesity using drugs whose mechanism includes the interaction and antagonism of the kainate/AMPA receptor. Methods are disclosed for employing the drug topiramate (topomax) as monotherapy or in combination therapy eith lamotrigene, valproic acid, valproic acid and carbamezepine combination, or felbamate (felbatol).
PCT/US2001/021509 2000-07-10 2001-07-09 Methods of producing weight loss and treatment of obesity WO2002003915A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002415760A CA2415760A1 (en) 2000-07-10 2001-07-09 Methods of producing weight loss and treatment of obesity
AU7325601A AU7325601A (en) 2000-07-10 2001-07-09 Methods of producing weight loss and treatment of obesity
AU2001273256A AU2001273256B2 (en) 2000-07-10 2001-07-09 Methods of producing weight loss and treatment of obesity
EP01952515A EP1305034A4 (en) 2000-07-10 2001-07-09 Methods of producing weight loss and treatment of obesity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/613,692 2000-07-10
US09/613,692 US6191117B1 (en) 2000-07-10 2000-07-10 Methods of producing weight loss and treatment of obesity

Publications (2)

Publication Number Publication Date
WO2002003915A2 WO2002003915A2 (en) 2002-01-17
WO2002003915A3 true WO2002003915A3 (en) 2002-05-23

Family

ID=24458316

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021509 WO2002003915A2 (en) 2000-07-10 2001-07-09 Methods of producing weight loss and treatment of obesity

Country Status (5)

Country Link
US (1) US6191117B1 (en)
EP (1) EP1305034A4 (en)
AU (2) AU7325601A (en)
CA (1) CA2415760A1 (en)
WO (1) WO2002003915A2 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
ATE348649T1 (en) * 2001-01-26 2007-01-15 Schering Corp COMBINATIONS OF A STEROL ABSORPTION INHIBITOR AND A PPAR ACTIVATOR FOR THE TREATMENT OF CARDIOVASCULAR INDICATIONS
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
CA2456331A1 (en) 2001-08-08 2003-02-20 Kevin R. Orton Apparatus and method for electrically conductive weight reduction
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
JP2005504043A (en) * 2001-08-10 2005-02-10 パラチン テクノロジーズ インク． Peptidomimetics of biologically active metal peptides
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
JP2005504091A (en) * 2001-09-21 2005-02-10 シェーリング　コーポレイション Treatment of xanthomas with azetidinone as a sterol absorption inhibitor
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
AU2003213719A1 (en) * 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
US6783766B2 (en) 2002-03-06 2004-08-31 Dow Global Technologies Inc. Process for preparing a cosmetic formulation
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
KR20110043664A (en) * 2002-05-17 2011-04-27 듀크 유니버시티 Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
MXPA05000232A (en) * 2002-06-21 2005-06-17 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution.
US7053066B2 (en) 2002-08-23 2006-05-30 Heartland Health Solutions, Llc Food composition and weight loss method for treating obesity
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
JP2006519869A (en) * 2003-03-07 2006-08-31 シェーリング　コーポレイション Substituted azetidinone compounds, processes for preparing substituted azetidinone compounds, their formulations and uses
ES2318274T3 (en) * 2003-03-07 2009-05-01 Schering Corporation AZETIDINONA SUBSTITUTED COMPOUNDS, FORMULATIONS AND USE OF THE SAME FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA.
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
GB0307860D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
US7375111B2 (en) 2003-04-29 2008-05-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
GB0325175D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
CA2553207A1 (en) * 2004-01-13 2005-08-04 Kishore M. Gadde Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
ITMI20040876A1 (en) * 2004-04-30 2004-07-30 Univ Degli Studi Milano DEHACETYLASE-HDAC HISTONE INHIBITORS-WHICH HYPOLIPIDEMIZED AGENTS FOR THE THERAPY AND PREVENTION OF ARTERIOSCLEROSIS AND CARDIOVASCULAR DISEASES
JP2007536229A (en) * 2004-05-03 2007-12-13 デューク・ユニバーシティー Composition for acting on weight loss
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
JP5180092B2 (en) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
KR101735466B1 (en) 2006-11-09 2017-05-15 오렉시젠 세러퓨틱스 인크. Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
AR063958A1 (en) * 2006-11-09 2009-03-04 Orexigen Therapeutics Inc METHODS TO MANAGE MEDICATIONS FOR WEIGHT LOSS
US8298576B2 (en) 2006-11-17 2012-10-30 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
WO2008070670A2 (en) 2006-12-04 2008-06-12 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
WO2008090534A1 (en) * 2007-01-26 2008-07-31 Berand Limited Methods and compositions for inhibition of excessive weight gain, reduction of inappropriate eating behaviours and inhibition of binge eating for the treatment of obesity
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
JP2011521973A (en) * 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド Methods for treating visceral fat conditions
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
US9026531B2 (en) * 2012-04-17 2015-05-05 Cerner Innovation, Inc. Associating multiple data sources into a web-accessible framework
RS63569B1 (en) 2012-06-06 2022-10-31 Nalpropion Pharmaceuticals Llc Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9463173B2 (en) 2014-03-04 2016-10-11 The Johns Hopkins University Compositions and methods for treating obesity and obesity-related conditions
US10278948B1 (en) 2015-09-03 2019-05-07 Tian Xia Method for transnasal delivery of anticonvulsant and therapeutic treatments
EP3883546A1 (en) 2018-11-21 2021-09-29 Rosemont Pharmaceuticals Ltd Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
WO2023042887A1 (en) * 2021-09-15 2023-03-23 国立大学法人 琉球大学 Pharmaceutical composition for use in treating cognitive decline, excess weight, or obesity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753694A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2542868T3 (en) * 1999-06-14 2015-08-12 Vivus, Inc. Combination therapy for the treatment of diabetes associated with obesity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753694A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1305034A4 *

Also Published As

Publication number Publication date
EP1305034A2 (en) 2003-05-02
CA2415760A1 (en) 2002-01-17
AU2001273256B2 (en) 2006-10-05
US6191117B1 (en) 2001-02-20
WO2002003915A2 (en) 2002-01-17
AU7325601A (en) 2002-01-21
EP1305034A4 (en) 2004-09-22

Similar Documents

Publication Publication Date Title
WO2002003915A3 (en) Methods of producing weight loss and treatment of obesity
MXPA03007712A (en) Pharmaceutical salts.
NZ601544A (en) Combination therapy for the treatment of ocular neovascular disorders
WO2002036732A3 (en) Active variants of fgf with improved specificity
AU7709901A (en) Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilicdrugs
WO2005074547A3 (en) Inflatable porous implants and methods for drug delivery
ZA200401217B (en) Zero order controlled drug delivery system.
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
MXPA03007903A (en) Highly flexible transdermal therapeutic system having nicotine as active substance.
WO2003039539A3 (en) Use of endothelin receptor antagonists in the treatment of tumour diseases
EP1440689A3 (en) Treatment of neurotic disorders
EP1643999B8 (en) Pyridoxamine for use in the treatment of diabetic nephropathy in type ii diabetes
ATE286894T1 (en) 2H-1-BENZOPYRAN DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS
MXPA04001847A (en) Use of polysubstituted indan-1-ol systems for producing drugs used in the prophylaxis or treatment of obesity.
AU2002333447A1 (en) Use of polysubstituted indan-1-ol systems for producing drugs in the prophylaxis or treatment of obesity
HUP0202016A3 (en) Taxane derivatives, the use of them for producing anti-cancer medicaments, these medicaments and processes for preparation of these derivatives
HUP0303597A3 (en) Diposable vaginal cannula for the simultaneous administration of drugs in different forms
WO2001060343A3 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
HK1049167A1 (en) Spherical telithromycin clusters, method for the producing and use thereof in the preparation of pharmaceutical forms.
WO2003075830A3 (en) Oral controlled drug delivery system containing carbamazepine
AU2001232053A1 (en) System for the extracorporeal treatment of blood
MXPA03003032A (en) Combination therapy for the treatment of estrogen-sensitive disease.
WO2004090537A3 (en) Methods to individualize combination therapy
WO2001064165A3 (en) Il-8 receptor antagonists
TWI256388B (en) Pharmaceutical combination

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2415760

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001273256

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001952515

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001952515

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP